Cryolife Inc (CRY) Director Sells $38,393.58 in Stock

Cryolife Inc (NYSE:CRY) Director C Elkins Ronald sold 1,154 shares of the business’s stock in a transaction that occurred on Friday, August 10th. The stock was sold at an average price of $33.27, for a total value of $38,393.58. Following the sale, the director now directly owns 69,843 shares in the company, valued at approximately $2,323,676.61. The sale was disclosed in a legal filing with the SEC, which is available through this link.

C Elkins Ronald also recently made the following trade(s):

  • On Thursday, June 14th, C Elkins Ronald sold 5,000 shares of Cryolife stock. The stock was sold at an average price of $28.89, for a total value of $144,450.00.
  • On Wednesday, May 30th, C Elkins Ronald sold 3,000 shares of Cryolife stock. The stock was sold at an average price of $27.18, for a total value of $81,540.00.

Shares of NYSE:CRY opened at $32.10 on Tuesday. The company has a market cap of $1.21 billion, a PE ratio of 105.97 and a beta of 0.73. The company has a debt-to-equity ratio of 0.80, a quick ratio of 3.63 and a current ratio of 4.97. Cryolife Inc has a 12 month low of $16.80 and a 12 month high of $34.15.

Cryolife (NYSE:CRY) last announced its quarterly earnings results on Monday, August 6th. The medical equipment provider reported $0.10 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.07 by $0.03. The business had revenue of $68.50 million for the quarter, compared to analyst estimates of $64.08 million. Cryolife had a positive return on equity of 4.28% and a negative net margin of 2.34%. The company’s quarterly revenue was up 43.2% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.12 EPS. analysts expect that Cryolife Inc will post 0.31 EPS for the current fiscal year.

Large investors have recently made changes to their positions in the company. BlackRock Inc. raised its position in shares of Cryolife by 14.5% during the 2nd quarter. BlackRock Inc. now owns 5,103,601 shares of the medical equipment provider’s stock worth $142,135,000 after purchasing an additional 645,825 shares during the last quarter. Pier Capital LLC acquired a new position in shares of Cryolife during the 2nd quarter worth approximately $5,839,000. Monarch Partners Asset Management LLC raised its position in shares of Cryolife by 190.4% during the 2nd quarter. Monarch Partners Asset Management LLC now owns 102,854 shares of the medical equipment provider’s stock worth $2,864,000 after purchasing an additional 67,434 shares during the last quarter. EAM Global Investors LLC acquired a new position in shares of Cryolife during the 2nd quarter worth approximately $1,472,000. Finally, Goldman Sachs Group Inc. raised its position in shares of Cryolife by 82.0% during the 4th quarter. Goldman Sachs Group Inc. now owns 110,825 shares of the medical equipment provider’s stock worth $2,123,000 after purchasing an additional 49,929 shares during the last quarter. 67.77% of the stock is currently owned by institutional investors and hedge funds.

Several brokerages have recently commented on CRY. Zacks Investment Research raised Cryolife from a “hold” rating to a “buy” rating and set a $37.00 price target on the stock in a research note on Monday. Canaccord Genuity boosted their price target on Cryolife from $28.00 to $36.00 and gave the stock a “buy” rating in a research note on Wednesday, August 8th. ValuEngine raised Cryolife from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, May 23rd. Finally, Northland Securities reissued a “buy” rating and set a $32.00 price target on shares of Cryolife in a research note on Tuesday, August 7th. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $32.75.

Cryolife Company Profile

CryoLife, Inc, together with its subsidiaries, manufactures, processes, and distributes medical devices and implantable human tissues for use in cardiac and vascular surgeries worldwide. The company operates in two segments, Medical Devices and Preservation Services. It offers BioGlue, an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X mechanical heart valves for aortic and mitral indications; cardiac preservation services; PhotoFix, a bovine pericardial patch for use in cardiac and vascular repairing activities; and PerClot, an absorbable powdered hemostat for use in surgical procedures, including cardiac, vascular, orthopedic, neurological, gynecological, ENT, and trauma surgeries.

Further Reading: Are analyst ratings accurate?

Insider Buying and Selling by Quarter for Cryolife (NYSE:CRY)

Receive News & Ratings for Cryolife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply